Opinion|Videos|June 9, 2025
Patient Experiences and Considerations for Axatilimab Therapy in Steroid-Refractory cGVHD
Panelists discuss how axatilimab demonstrates particularly good responses for gastrointestinal graft-vs-host disease (GVHD) and may improve sclerotic skin changes despite lower rates of overall skin response.
Advertisement
Episodes in this series
Clinical Experience with Newer Agents
The final segment covers the panelists’ perspectives on the AGAVE-201 trial data and early clinical experience with axatilimab. They note:
- Strong efficacy in gastrointestinal manifestations of chronic GVHD
- Efficacy in heavily pretreated patients (85% had prior ruxolitinib/ibrutinib/belumosudil)
- Different mechanism of action provides new options for refractory disease
- Early clinical experience shows good tolerability
- Potential adverse events to monitor: liver enzyme elevations, infusion reactions, periorbital edema
The panel discusses the practical aspects of intravenous administration (every 2 weeks) and their approaches to sequential vs combination therapy. Most prefer to add axatilimab while maintaining current therapy, then gradually tapering prior agents, though practices vary between centers.
Advertisement
Related to this article
Sunvozertinib is FDA approved for patients with NSCLC with EGFR exon 20 insertion mutations that progressed on or after platinum-based chemotherapy.
Vopimetostat yielded favorable outcomes in a phase 1/2 trial in combination with daraxonrasib or zoldonrasib in MTAP-deleted, RAS-mutant pancreatic cancer or lung cancer.
The phase 2 I-SPY2.2 trial found promising responses with rilvegostomig plus trastuzumab deruxtecan in biomarker-defined, immune-positive tumors.
Early multidisciplinary survivorship care during radiotherapy boosts adherence and improves disease-free survival in head and neck cancer, with lower recurrence risk.
Adding the mRNA-based individualized neoantigen intismeran to pembrolizumab reduced the risk of disease recurrence or death by 42% in melanoma.
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The FDA converted the accelerated approval of pembrolizumab in TMB-high solid tumors to traditional approval, redefining TMB-high as at least 13 mut/Mb.
Following an end-of-phase 2 meeting with the FDA, Rgenta plans to start a phase 3 trial of oral RGT-61159 in adenoid cystic carcinoma in the first quarter of 2027.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Personalized mRNA Vaccine Intismeran Plus Pembro Cuts Melanoma Recurrence
2
Vopimetostat Plus Daraxonrasib Yields 82% ORR in MTAP-Deleted PDAC
3
Sunvozertinib Now Available in US for EGFR Exon 20 Insertion NSCLC
4
Rilvegostomig Combo Helped Some Patients Avoid Chemotherapy in Early Breast Cancer
5